Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study)

Am J Cardiol. 2004 Oct 1;94(7):947-51. doi: 10.1016/j.amjcard.2004.06.038.

Abstract

The Framingham Heart Study records of participants with atrial fibrillation (AF) during 1980 and 1994 were retrospectively reviewed to determine the prevalence of warfarin and aspirin use in AF. Anticoagulant use increased significantly in the 393 men and women (mean ages 72.5 and 79.0 years, respectively) who developed AF over the observation period: aspirin use increased from 14% to 39% in men and from 19% to 33% in women, and warfarin use increased from 10% to 39% in men and from 17% to 38% in women. There were no significant gender differences in anticoagulant use (p = 0.61), but participants using warfarin were younger. A total of 65 participants (17%) had major bleeding complications <or=5 years after initial AF. Age was not a significant predictor of bleeding.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anticoagulants / adverse effects*
  • Aspirin / adverse effects*
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / epidemiology
  • Female
  • Gastrointestinal Hemorrhage / chemically induced*
  • Gastrointestinal Hemorrhage / epidemiology
  • Heart Failure / drug therapy
  • Heart Failure / epidemiology
  • Humans
  • Intracranial Hemorrhages / chemically induced*
  • Intracranial Hemorrhages / epidemiology
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / adverse effects*
  • Predictive Value of Tests
  • Prevalence
  • Retrospective Studies
  • Risk Factors
  • Survival Analysis
  • Treatment Outcome
  • Warfarin / adverse effects*

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors
  • Warfarin
  • Aspirin